Under the Poisons Standard (the current version of which is maintained by the Therapeutic Goods Administration and given legislative force through the Therapeutic Goods Act 1989 and state/territory scheduling laws), a Schedule 9 listing signals that a substance has a high potential for abuse or misuse and no currently accepted therapeutic application warranting broader access. Handling a Schedule 9 substance outside an approved framework is a criminal offence under Australian law; penalties vary by state and territory but can include substantial fines and imprisonment.
Psilocybin (the active compound found in certain fungi) and MDMA are among the substances listed in Schedule 9. From 1 July 2023, the TGA authorised a narrow rescheduling pathway: psychiatrists who have been approved as Authorised Prescribers (AP) under the TGA's Authorised Prescriber scheme may prescribe psilocybin (reclassified to Schedule 8 for this specific purpose) for treatment-resistant depression, and MDMA (also reclassified to Schedule 8) for post-traumatic stress disorder, within a tightly regulated clinical setting. Outside of that AP framework or an approved clinical trial, both substances remain Schedule 9 prohibited substances; possession or supply by any other person is a criminal offence.
Published clinical research , including studies reported in peer-reviewed journals such as JAMA Psychiatry and The Lancet Psychiatry , has investigated psilocybin under controlled, ethics-approved conditions. Those study protocols are designed and supervised by credentialled clinicians and research institutions; they are not replicable in non-clinical settings, and the doses and procedures reported in such literature cannot be interpreted as instructions or recommendations for any other use. Adverse outcomes including acute psychological distress, persisting perceptual disturbances, and exacerbation of pre-existing mental health conditions have been documented in both research and community-use accounts.
The Schedule 9 / Schedule 8 (AP pathway) distinction is frequently misunderstood. The 2023 regulatory change does not legalise or decriminalise psilocybin or MDMA for general use. It creates one lawful access route , through a TGA-approved Authorised Prescriber in a clinical context; while leaving all other possession, production, and supply unlawful. Anyone seeking information about the Authorised Prescriber scheme should consult the TGA's published guidance directly.
Sources: